BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
ZEAL.CO upcoming catalysts
Zealand Pharma: 0 upcoming industry Phase 2/3 trial readout(s) in the next 90 days (0 Phase 3), 0 upcoming FDA decision event(s), and in the last 12 months 3 readout(s) and 1 FDA event(s). Subscribe to ZEAL.CO (.ics).
Upcoming FDA decision events
| Date | Event | Status | Company | Drug | Source |
|---|
| No upcoming PDUFA date or AdCom found. |
Upcoming trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|
| No trials in this window. |
FDA decision events, last 12 months
Trial readouts, last 12 months
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|
| 2026-08-13 | P2 | Zealand Pharma ZEAL.CO | NCT06926842 Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2) | Overweight; Type 2 Diabetes; Obesity | completed | 221 |
| 2026-04-30 | P3 | Zealand Pharma ZEAL.CO | NCT04881825 Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS - Extension Trial | Short Bowel Syndrome | completed | 84 |
| 2026-04-30 | P3 | Zealand Pharma ZEAL.CO | NCT03905707 Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS | Short Bowel Syndrome | completed | 150 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.